NCT02159755 2026-03-19
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT01695941 2026-03-18
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01955499 2025-11-10
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting